Group 1 - Watson Bio's stock increased by 5.44%, reaching 13.17 CNY per share, with a trading volume of 588 million CNY and a turnover rate of 2.99%, resulting in a total market capitalization of 21.063 billion CNY [1] - The company, Yunnan Watson Bio-Tech Co., Ltd., was established on January 16, 2001, and listed on November 12, 2010. Its main business involves the research, production, and sales of vaccine products [1] - The revenue composition of Watson Bio includes 94.82% from self-developed vaccine products, 4.67% from intermediate products, 0.26% from other supplementary products, and 0.24% from technical services [1] Group 2 - According to data, one fund under Penghua Fund has a significant holding in Watson Bio. The Biovaccine ETF (159657) reduced its holdings by 78,600 shares in the third quarter, now holding 581,300 shares, which accounts for 5.71% of the fund's net value, ranking it as the fifth-largest holding [2] - The Biovaccine ETF (159657) was established on February 22, 2023, with a current size of 118 million CNY. Year-to-date, it has achieved a return of 10.75%, ranking 3652 out of 4216 in its category; over the past year, it has incurred a loss of 0.67%, ranking 3697 out of 3922; since inception, it has lost 29.12% [2] - The fund manager of the Biovaccine ETF is Lin Song, who has been in the position for 2 years and 136 days. The total asset size under his management is 1.777 billion CNY, with the best fund return during his tenure being 22.42% and the worst being -15.21% [2]